LT3091029T - Anti-il13 antikūno kompozicijos - Google Patents

Anti-il13 antikūno kompozicijos

Info

Publication number
LT3091029T
LT3091029T LTEP16169916.0T LT16169916T LT3091029T LT 3091029 T LT3091029 T LT 3091029T LT 16169916 T LT16169916 T LT 16169916T LT 3091029 T LT3091029 T LT 3091029T
Authority
LT
Lithuania
Prior art keywords
antibody compositions
antibody
compositions
Prior art date
Application number
LTEP16169916.0T
Other languages
English (en)
Inventor
Ajay Deshmukh
Joumana ZEID
Thomas M. SCHERER
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of LT3091029T publication Critical patent/LT3091029T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
LTEP16169916.0T 2011-10-31 2012-10-30 Anti-il13 antikūno kompozicijos LT3091029T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161553916P 2011-10-31 2011-10-31

Publications (1)

Publication Number Publication Date
LT3091029T true LT3091029T (lt) 2023-02-27

Family

ID=48192677

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16169916.0T LT3091029T (lt) 2011-10-31 2012-10-30 Anti-il13 antikūno kompozicijos

Country Status (27)

Country Link
US (4) US10000562B2 (lt)
EP (3) EP4218937A3 (lt)
JP (4) JP6120452B2 (lt)
KR (4) KR102259829B1 (lt)
CN (4) CN109078182B (lt)
AR (2) AR088579A1 (lt)
AU (3) AU2012332767C1 (lt)
BR (1) BR112014008864B1 (lt)
CA (2) CA2849210C (lt)
DK (1) DK3091029T5 (lt)
ES (1) ES2936387T3 (lt)
FI (1) FI3091029T3 (lt)
HK (1) HK1201857A1 (lt)
HR (1) HRP20230153T1 (lt)
HU (1) HUE061728T2 (lt)
IL (2) IL232053B (lt)
LT (1) LT3091029T (lt)
MX (2) MX363226B (lt)
MY (2) MY197851A (lt)
PL (1) PL3091029T3 (lt)
PT (1) PT3091029T (lt)
RS (1) RS63948B1 (lt)
RU (1) RU2665810C2 (lt)
SG (1) SG11201401903PA (lt)
SI (1) SI3091029T1 (lt)
WO (1) WO2013066866A1 (lt)
ZA (2) ZA201401779B (lt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
WO2013066426A2 (en) 2011-06-24 2013-05-10 Kci Licensing, Inc. Reduced-pressure dressings employing tissue-fixation elements
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
HUE037811T2 (hu) 2011-10-28 2018-09-28 Prothena Biosciences Ltd Alfa-szinukleint felismerõ humanizált antitestek
LT3091029T (lt) 2011-10-31 2023-02-27 F. Hoffmann-La Roche Ag Anti-il13 antikūno kompozicijos
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
CN108517010A (zh) 2012-01-27 2018-09-11 普罗典娜生物科学有限公司 识别α-突触核蛋白的人源化抗体
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
KR102332302B1 (ko) 2013-09-13 2021-12-01 제넨테크, 인크. 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
SG10201802525QA (en) * 2013-09-13 2018-04-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
JPWO2015079977A1 (ja) * 2013-11-26 2017-03-16 シャープ株式会社 抗体分離方法、抗体評価方法、医薬の評価方法、及び、抗体の２次元電気泳動用キット
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
ES2788999T5 (en) 2014-12-23 2025-02-24 Merz Pharma Gmbh & Co Kgaa Botulinum toxin prefilled container
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
WO2018039591A1 (en) * 2016-08-25 2018-03-01 California Institute Of Technology Ascaroside treatment of autoimmune and inflammatory diseases
CA3031589C (en) 2016-09-23 2025-05-06 Genentech, Inc. USES OF IL-13 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DERMATITIS
CN120392659A (zh) * 2017-01-11 2025-08-01 赛特瑞恩股份有限公司 稳定的液体调配物
JP2019048091A (ja) * 2018-10-23 2019-03-28 ニプロ株式会社 デクスメデトミジン注射液を充填したプレフィルドシリンジ
WO2020142096A1 (en) * 2019-01-02 2020-07-09 M & J Scientific, Llc Light scattering detectors and methods for the same
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
CA3159377A1 (en) * 2019-11-26 2021-06-03 David S. Soane Excipient compounds for biopolymer formulations
WO2022087610A1 (en) * 2020-10-22 2022-04-28 Allakos Inc. Anti-siglec-8 antibody formulations
TWI847170B (zh) 2021-07-16 2024-07-01 美商德米拉股份有限公司 用於治療異位性皮炎之il-13抗體
TWI859566B (zh) 2021-08-13 2024-10-21 美商德米拉股份有限公司 用於治療異位性皮膚炎之il-13抗體
IL311027A (en) 2021-09-15 2024-04-01 Dermira Inc Il-13 inhibitors for the treatment of prurigo nodularis
IL316779A (en) 2022-05-05 2025-01-01 Dermira Inc IL-13 antibodies for the treatment of atopic dermatitis
JP2025522482A (ja) 2022-06-17 2025-07-15 アポジー バイオロジクス， インコーポレイテッド インターロイキン１３に結合する抗体及び使用方法
EP4676532A1 (en) 2023-03-08 2026-01-14 Dermira, Inc. Il-13 antibodies for the treatment of atopic dermatitis
WO2025076280A1 (en) 2023-10-05 2025-04-10 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders
TW202544035A (zh) 2023-12-14 2025-11-16 美商德米拉股份有限公司 用於治療全年性過敏性鼻炎之il-13抗體
WO2025128984A1 (en) 2023-12-14 2025-06-19 Dermira, Inc. Il-13 antibodies for the treatment of chronic rhinosinusitis with nasal polyps
WO2025137523A2 (en) * 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical formulations of antibodies that bind interleukin 13
TW202535935A (zh) * 2023-12-20 2025-09-16 美商艾普吉醫療股份有限公司 結合介白素13之抗體之醫藥組合物
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2025155802A1 (en) * 2024-01-19 2025-07-24 Allakos Inc. Anti-siglec-6 antibody formulations
WO2025184453A1 (en) 2024-03-01 2025-09-04 Dermira, Inc. Il-13 antibodies for the treatment of post-inflammatory hyperpigmentation or hypopigmentation of skin

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
JPH08503950A (ja) 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
ES2151079T3 (es) 1994-09-09 2000-12-16 Takeda Chemical Industries Ltd Preparacion de liberacion sostenida que contiene una sal metalica de un peptido.
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996040072A2 (en) 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
RU2319503C2 (ru) * 2001-11-07 2008-03-20 Цитос Байотекнолоджи Аг Композиция для иммунизации (варианты), способ ее получения и применение для лечения аллергических эозинофильных заболеваний
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
ES2304602T3 (es) 2003-02-28 2008-10-16 Ares Trading S.A. Formulaciones liquidas de la proteina de union al factor de necrosis tumoral tbp-1.
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
AR045614A1 (es) * 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
DK2805728T3 (da) * 2003-12-23 2020-04-20 Genentech Inc Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2007036745A2 (en) 2005-09-30 2007-04-05 Medimmune Limited Interleukin-13 antibody composition
MY144906A (en) * 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
CN101378782A (zh) * 2005-12-21 2009-03-04 惠氏公司 粘度降低的蛋白质制剂及其用途
TWI395754B (zh) * 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
EP2114451A2 (en) * 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Anti-il-13 antibody formulations and uses thereof
CA2676881C (en) * 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
HRP20140204T1 (hr) * 2008-12-03 2014-04-11 Astellas Deutschland Gmbh Oralni oblici doziranja bendamustina
AU2010221156A1 (en) * 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
CN106983862A (zh) * 2010-03-22 2017-07-28 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
RU2012151500A (ru) 2010-05-03 2014-06-10 Дженентек, Инк. Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
CN103501825B (zh) 2011-05-02 2017-03-15 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
LT3091029T (lt) * 2011-10-31 2023-02-27 F. Hoffmann-La Roche Ag Anti-il13 antikūno kompozicijos

Also Published As

Publication number Publication date
BR112014008864A2 (pt) 2018-08-07
US10000562B2 (en) 2018-06-19
AU2012332767A1 (en) 2014-04-10
KR20140084078A (ko) 2014-07-04
HUE061728T2 (hu) 2023-08-28
IL276234B (en) 2022-04-01
JP6120452B2 (ja) 2017-04-26
KR20170096212A (ko) 2017-08-23
KR20200065104A (ko) 2020-06-08
AU2016210757A1 (en) 2016-08-25
BR112014008864B1 (pt) 2021-11-09
EP3091029B1 (en) 2022-12-28
JP6921148B2 (ja) 2021-08-18
ZA201901490B (en) 2021-06-30
IL276234A (en) 2020-09-30
EP2773662A1 (en) 2014-09-10
RU2665810C2 (ru) 2018-09-04
KR102259829B1 (ko) 2021-06-03
US12492247B2 (en) 2025-12-09
JP6272950B2 (ja) 2018-01-31
US20210155684A1 (en) 2021-05-27
CN116077644A (zh) 2023-05-09
RS63948B1 (sr) 2023-02-28
CN109078182A (zh) 2018-12-25
CN104039826A (zh) 2014-09-10
CA2849210A1 (en) 2013-05-10
MX363226B (es) 2019-03-15
KR101994809B1 (ko) 2019-07-01
AU2018232943A1 (en) 2018-10-11
AU2012332767C1 (en) 2017-02-02
AR088579A1 (es) 2014-06-18
JP2019203002A (ja) 2019-11-28
DK3091029T5 (da) 2024-10-14
HRP20230153T1 (hr) 2023-03-31
EP2773662A4 (en) 2015-07-01
US20190002552A1 (en) 2019-01-03
JP2018048166A (ja) 2018-03-29
ES2936387T3 (es) 2023-03-16
AU2012332767B2 (en) 2016-05-12
MY187874A (en) 2021-10-26
CA2849210C (en) 2020-07-14
ZA201401779B (en) 2019-07-31
IL232053B (en) 2020-08-31
HK1201857A1 (en) 2015-09-11
CA3078979A1 (en) 2013-05-10
JP2016193922A (ja) 2016-11-17
KR20190077127A (ko) 2019-07-02
US20260055178A1 (en) 2026-02-26
WO2013066866A1 (en) 2013-05-10
FI3091029T3 (fi) 2023-03-20
AU2018232943B2 (en) 2020-07-23
PL3091029T3 (pl) 2023-04-11
SG11201401903PA (en) 2014-05-29
CN108704132A (zh) 2018-10-26
NZ622654A (en) 2017-01-27
DK3091029T3 (da) 2023-01-30
PT3091029T (pt) 2023-02-03
US20140348855A1 (en) 2014-11-27
MY197851A (en) 2023-07-20
JP2014532664A (ja) 2014-12-08
EP3091029A1 (en) 2016-11-09
MX2019002979A (es) 2020-02-10
US10947307B2 (en) 2021-03-16
SI3091029T1 (sl) 2023-03-31
CN109078182B (zh) 2022-08-12
AR124140A2 (es) 2023-02-15
EP4218937A2 (en) 2023-08-02
IL232053A0 (en) 2014-05-28
MX2014004992A (es) 2014-08-27
CA3078979C (en) 2022-10-11
EP4218937A3 (en) 2023-10-25
RU2014116070A (ru) 2015-12-10

Similar Documents

Publication Publication Date Title
LT3091029T (lt) Anti-il13 antikūno kompozicijos
LT2791160T (lt) Modifikuotos mrnr sudėtys
LT2742151T (lt) Polimerazės kompozicija
BR112013022112A2 (pt) composição
BR112013022102A2 (pt) composição
DK2686017T3 (da) Oftalmisk sammensætning
BR112014004395A2 (pt) composição
BR112014003052A2 (pt) composições farmacêuticas
BR112013017183A2 (pt) composições de bepostatina
DK2694038T3 (da) Farmaceutisk sammensætning
CO6970594A2 (es) Composiciones hemostáticas
PT2720563T (pt) Resumo
EP2729131A4 (en) TOPICAL COMPOSITIONS
DK3513803T3 (da) Hæmostatiske sammensætninger
PT2543357T (pt) Resumo
CO6930367A2 (es) Composiciones farmaceúticas
CO6930368A2 (es) Composiciones de yodo-povidona estable
CO6862152A2 (es) Composición limpiadora
SMT201700110B (it) Composizione immunogena
BR112013033808A2 (pt) composição
HUE040370T2 (hu) Gyógyszerkészítmények
EP2786976A4 (en) MONOLITHIC COMPOSITION
BR112014000015A2 (pt) formulação
FI11374U1 (fi) Bensiinikoostumukset
EP2730619A4 (en) COMPOSITION